why choose us

First received: March 06, 2023

Clinical Trial: Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG

Study Status: Completed

Recruit Status: RECRUITING

Condition: High Grade Glioma

Study Type: INTERVENTIONAL


Official Title: A Phase 0, Single-center, Open-label, Dose-escalating Trial Using Super-selective Intra-arterial Infusion of a Single Dose of Temsirolimus for the Treatment of Recurrent High-grade Glioma

Brief Summary: This is a single-center, open-label, dose-escalating Phase 0 trial that will enroll participants with a confirmed diagnosed recurrent high-grade glioma (grade 3 or 4 per WHO criteria) targeting the mTOR pathway.Eligible participants will be administered a single infusion of temsirolimus through super-selective intra-arterial infusion or intravenous infusion.Participants will receive the study drug administration on the same day as the planned surgical resection of the tumor.

Read more